Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Fineline Cube May 19, 2026
Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Fineline Cube May 19, 2026
Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Fineline Cube May 19, 2026
Company Deals

Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial

Fineline Cube May 19, 2026
Company Deals

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

Fineline Cube May 19, 2026
Company Drug

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

Fineline Cube May 19, 2026
Company Deals

PHASE Scientific Partners with Lumos Diagnostics to Launch FebriDx in US Respiratory Market

Fineline Cube Jul 17, 2025

China-based PHASE Scientific has entered into an exclusive distribution agreement with Lumos Diagnostics to introduce...

Company Drug

Daiichi Sankyo and AstraZeneca Submit Enhertu Application for HER2-Positive Gastric Cancer in China

Fineline Cube Jul 17, 2025

Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have submitted a supplemental new-drug application...

Company

Johnson & Johnson Reports 5.8% Sales Growth in 2025Q2, Increases Full-Year Guidance

Fineline Cube Jul 17, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced its second-quarter 2025 (2025Q2) results, reporting...

Company Policy / Regulatory

Konruns’ KC1036 Proposed for CDE’s SPARK Program to Accelerate Pediatric Ewing’s Sarcoma Treatment Development

Fineline Cube Jul 17, 2025

Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced on Wednesday that China’s Center for Drug...

Company Drug

Hainan Boao Research Hospital Secures Approval for China’s First Medical-Food Import for Rare Metabolic Disorders

Fineline Cube Jul 17, 2025

Hainan Boao Research Hospital, operated by Shanghai’s Ruijin Hospital, has obtained provincial approval to import...

Company Drug

Sanofi’s Gene Therapy SAR446597 Secures FDA Fast Track for Geographic Atrophy

Fineline Cube Jul 17, 2025

France-based Sanofi (NASDAQ: SNY) announced that its one-time intravitreal gene therapy SAR446597 has received FDA...

Company Deals

Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development

Fineline Cube Jul 16, 2025

China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40...

Company Drug

Hengrui Pharma and Kailera Announce Positive Phase III Results for HRS9531 in Obesity Treatment

Fineline Cube Jul 16, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc....

Company Drug

Haisco Pharma Receives FDA Approval for Clinical Trials of Autoimmune Drug HSK47388

Fineline Cube Jul 16, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...

Company Deals

Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System

Fineline Cube Jul 16, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between...

Company Drug

AstraZeneca’s Baxdrostat Meets Primary and Secondary Endpoints in Phase III BaxHTN Trial

Fineline Cube Jul 16, 2025

UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that baxdrostat has achieved both primary and secondary endpoints in the...

Company Medical Device

Shanghai Sanyou Medical Receives NMPA Marketing License for JAZZ Spinal Fixation System

Fineline Cube Jul 16, 2025

Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced that it has received the marketing license...

Policy / Regulatory

NMPA Updates Reference Drugs for GQCE Evaluation: 42 New Additions and 6 Removals

Fineline Cube Jul 16, 2025

China’s National Medical Products Administration (NMPA) has released the 94th batch of reference drugs for...

Company Deals

BD Merges Biosciences & Diagnostic Solutions with Waters Corporation in USD 17.5 Billion Deal

Fineline Cube Jul 16, 2025

US major Becton, Dickinson and Co., (BD) is set to merge its Biosciences & Diagnostic...

Company Deals

Sino Biopharmaceutical Acquires Majority Stake in LaNova Medicines for USD 950.92 Million

Fineline Cube Jul 16, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acquisition of a 95.09% stake in Shanghai-based...

Company Drug

Vigonvita’s Simenafil Receives NMPA Approval for Erectile Dysfunction Treatment

Fineline Cube Jul 16, 2025

Suzhou-based Vigonvita Life Sciences Co., Ltd., announced that it has received marketing approval from the...

Company Deals

Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development

Fineline Cube Jul 16, 2025

Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care...

Company Deals

Otsuka to Acquire Cantargia’s IL-1RAP Monoclonal Antibody CAN10 for Autoimmune Diseases

Fineline Cube Jul 16, 2025

Japan-based drug maker Otsuka (OTCMKTS: OTSKY) is set to acquire from Swedish biotech Cantargia AB...

Company Drug

Huadong Medicine Receives FDA Approval for Clinical Trials of Innovative ADC HDM2020

Fineline Cube Jul 15, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...

Company Deals

Ningbo Health Gene and Biofast Biotech Partner to Advance Genetic Testing for Hereditary Diseases

Fineline Cube Jul 15, 2025

Chinese firms Ningbo Health Gene Technologies Co., Ltd. and Biofast Biotechnology Co., Ltd. announced late...

Posts pagination

1 … 128 129 130 … 667

Recent updates

  • Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure
  • BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader
  • China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases
  • Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial
  • Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui’s HER3-Targeting ADC SHR-A2009 Achieves Phase III Success in EGFR-Mutated NSCLC After TKI Failure

Company Deals

BrightGene Pursues Hong Kong Secondary Listing as Global API and Intermediates Leader

Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Company Drug

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.